Cladribine Induction Therapy Improves Prognosis in IDH2 Mutant NK-AML Patients
1. Overview Acute myeloid leukemia (AML) is a malignant clonal disease of hematopoietic stem/progenitor cells. Approximately 20% of AML patients have mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2), which lead to DNA hypermethylation and epigenetic abnormalities, thereby inhibiting hematopoietic cell differentiation, making it an early event in AML. However, the prognostic value of IDH … Read more